The aim of the present study is to compare the pharmacokinetics of nicardipine liquisolid tablets with its conventional tablets. 8 rats were taken, all the rats were having body weight approximately 200-260gr. Randomized Balanced Incomplete Block Design (BIBD) method was selected to determine pharmacokinetics of nicardipine liquisolid compact tablets. Blood samples were taken at predefined sampling points 0–24h after medication, and the plasma concentrations of nicardipine liquid solid compact tablets, conventional tablets were determined by high-performance liquid chromatography. The liquisolid compact tablets increased in Cmax and AUC were observed, tmax occurred at 1.844 and 2.219 h with liquid solid compact tablets and conventional tablets. The area under the plasma concentration-time curve extrapolated to infinity AUC (0−∞) of liquisolid compact tablets was shown more than its conventional tablets. This research showed that formulation of nicardipine liquisolid compact tablets shown increase of bioavailability.